SURVEYING CHANGES IN HCV CORE ANTIGEN (HCVcAg) CONCENTRATIONS DURING DAAs TREATMENT IN PEOPLE WITH HEPATITIS C VIRUS

Thị Hường Dương , Vũ Huy Bùi , Văn Dũng Nguyễn

Main Article Content

Abstract

Objective: Observing changes in HCVcAg kinetics during DAAs treatment in patients with hepatitis C virus. Subjects   and methods: A  cross sectional  descriptive  study use of convenience sampling method was  performed  on 36 patients  ≥16 years old diagnosed with hepatitis C treated with DAAs and monitored at the Center for Tropical Diseases - Bach Mai Hospital. HCVcAg, HCV RNA and other hematological biochemical tests were evaluated at the following times: before, 4 weeks, 12 weeks of treatment and after 3-6 months upon completion of treatment. Results and conclusions: The level of HCVcAg was 5260.54 ± 4421.98 fmol/L. HCVcAg levels decreased rapidly during DAAs treatment. At 4 weeks, 30/33 cases did not detect HCVcAg, at 12 weeks and after the end of treatment, no case detected HCVcAg.

Article Details

References

1. Stasi C, Silvestri C, Voller F. Update on Hepatitis C Epidemiology: Unaware and Untreated Infected Population Could Be the Key to Elimination. SN Comprehensive Clinical Medicine. 2020; 2(12):2808-2815. doi:10.1007/s42399-020-00588-3
2. Guidelines on hepatitis B and C testing. World Health Organization; 2017.
3. Łucejko M, Flisiak R. Quantitative Measurement of HCV Core Antigen for Management of Interferon-Free Therapy in HCV-Infected Patients. Antiviral Therapy. 2018;23(2):149-156. doi:10.3851/imp3190
4. Nhàn LTT, Lợi TV, Duy LTT, Đạt NQ, Hà NM. Giá trị của xét nghiệm HCV core antigen trong sàng lọc vi rút viêm gan C. Tạp chí Y học Việt Nam. 07/31 2022;516(2) doi:10. 51298/vmj. v516i2.3088
5. Quyết định số 5314/QĐ-BYT Quyết định về việc ban hành Hướng dẫn chẩn đoán, điều trị bệnh viêm gan vi rút C (Bộ Y Tế) (2021).
6. Ko P-H, Tseng C-W, Tseng K-C, Chen Y-C, Hsu C-S. The utility of HCV core antigen for evaluation of viremia at 48 weeks posttreatment with direct-acting antivirals. Advances in Digestive Medicine. 2023;10(2): 80-86. doi:https://doi.org/ 10.1002/aid2.13316
7. Khudyakov YE, Ponnuvel S, Prakash A, et al. Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAs. PloS one. 2023;18(2):e0282013. doi:10.1371/journal.pone.0282013
8. Nevine I. Musaa ES, Ramy S. Ghaita, Heba Alyb, Dalia H. Abdelhamid. Can hepatitis C virus core antigen replace quantitative RNA in the assessment of a sustained virologic response? The Egyptian Journal of Internal Medicine. 2020;ol. 31 No. 4doi:10.4103/ejim.ejim_88_19
9. Feng B, Yang R-F, Xie Q, et al. Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection. BMC Gastroenterology. 2014/03/13 2014;14(1):47. doi:10.1186/1471-230X-14-47
10. Nguyen THT, Guedj J, Uprichard SL, Kohli A, Kottilil S, Perelson AS. The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics? Scientific Reports. 2017/08/31 2017;7(1): 10233. doi: 10.1038/ s41598-017-09776-z